|
1
|
Teague A, Lim KH and Wang-Gillam A:
Advanced pancreatic adenocarcinoma: A review of current treatment
strategies and developing therapies. Ther Adv Med Oncol. 7:68–84.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ryan DP, Hong TS and Bardeesy N:
Pancreatic adenocarcinoma. N Engl J Med. 371:1039–1049. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yeo TP: Demographics, epidemiology, and
inheritance of pancreatic ductal adenocarcinoma. Semin Oncol.
42:8–18. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
He XY and Yuan YZ: Advances in pancreatic
cancer research: Moving towards early detection. World J
Gastroenterol. 20:11241–11248. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yilmaz M and Christofori G: Mechanisms of
motility in metastasizing cells. Mol Cancer Res. 8:629–642. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Qian C, Liu F, Ye B, Zhang X, Liang Y and
Yao J: Notch4 promotes pancreatic cancer growth through activation
of Wnt1/β-catenin signaling. Mol Cell Biochem. 401:165–174. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Naik S, MacFarlane M and Sarin A: Notch4
signaling confers susceptibility to TRAIL induced apoptosis in
breast cancer cells. J Cell Biochem. 116:1371–1380. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ahn S, Hyeon J and Park CK: Notch1 and
Notch4 are markers for poor prognosis of hepatocellular carcinoma.
Hepatobiliary Pancreat Dis Int. 12:286–294. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim SH and Singh SV: The role of polycomb
group protein Bmi-1 and Notch4 in breast cancer stem cell
inhibition by benzyl isothiocyanate. Breast Cancer Res Treat.
149:681–692. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Manning BD and Cantley LC: AKT/PKB
signaling: Navigating downstream. Cell. 129:1261–1274. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stegeman H, Span PN, Kaanders JH and
Bussink J: Improving chemoradiation efficacy by PI3-K/AKT
inhibition. Cancer Treat Rev. 40:1182–1191. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hafsi S, Pezzino FM, Candido S, Ligresti
G, Spandidos DA, Soua Z, McCubrey JA, Travali S and Libra M: Gene
alterations in the PI3K/PTEN/AKT pathway as a mechanism of
drug-resistance (review). Int J Oncol. 40:639–644. 2012.PubMed/NCBI
|
|
13
|
Brown KK, Montaser-Kouhsari L, Beck AH and
Toker A: MERIT40 is an Akt substrate that promotes resolution of
DNA damage induced by chemotherapy. Cell Rep. 11:1358–1366. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ramakrishnan G, Davaakhuu G, Chung WC, Zhu
H, Rana A, Filipovic A, Green AR, Atfi A, Pannuti A, Miele L and
Tzivion G: AKT and 14-3-3 regulate Notch4 nuclear localization. Sci
Rep. 5:87822015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao X, Gao S, Ren H, Sun W, Zhang H, Sun
J, Yang S and Hao J: Hypoxia-inducible factor-1 promotes pancreatic
ductal adenocarcinoma invasion and metastasis by activating
transcription of the actin-bundling protein fascin. Cancer Res.
74:2455–2464. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sheppard K, Kinross KM, Solomon B, Pearson
RB and Phillips WA: Targeting PI3 kinase/AKT/mTOR signaling in
cancer. Crit Rev Oncog. 17:69–95. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhou SL, Zhou ZJ, Hu ZQ, Li X, Huang XW,
Wang Z, Fan J, Dai Z and Zhou J: CXCR2/CXCL5 axis contributes to
epithelial-mesenchymal transition of HCC cells through activating
PI3K/Akt/GSK-3β/Snail signaling. Cancer Lett. 358:124–135. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Booth AK and Gutierrez-Hartmann A:
Signaling pathways regulating pituitary lactotrope homeostasis and
tumorigenesis. Adv Exp Med Biol. 846:37–59. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen W, Zhang H, Wang J, Cao G, Dong Z, Su
H, Zhou X and Zhang S: Lentiviral-mediated gene silencing of
Notch-4 inhibits in vitro proliferation and perineural invasion of
ACC-M cells. Oncol Rep. 29:1797–1804. 2013.PubMed/NCBI
|
|
20
|
Nagamatsu I, Onishi H, Matsushita S, Kubo
M, Kai M, Imaizumi A, Nakano K, Hattori M, Oda Y, Tanaka M and
Katano M: NOTCH4 is a potential therapeutic target for
triple-negative breast cancer. Anticancer Res. 34:69–80.
2014.PubMed/NCBI
|
|
21
|
Singh D, Upadhyay G, Srivastava RK and
Shankar S: Recent advances in pancreatic cancer: Biology,
treatment, and prevention. Biochim Biophys Acta. 1856:13–27.
2015.PubMed/NCBI
|
|
22
|
Damaskos C, Karatzas T, Kostakis ID,
Nikolidakis L, Kostakis A and Kouraklis G: Nuclear receptors in
pancreatic tumor cells. Anticancer Res. 34:6897–6911.
2014.PubMed/NCBI
|
|
23
|
Tang SC and Chen YC: Novel therapeutic
targets for pancreatic cancer. World J Gastroenterol.
20:10825–10844. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mann CD, Bastianpillai C, Neal CP, Masood
MM, Jones DJ, Teichert F, Singh R, Karpova E, Berry DP and Manson
MM: Notch3 and HEY-1 as prognostic biomarkers in pancreatic
adenocarcinoma. PLoS One. 7:e511192012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ding LC, She L, Zheng DL, Huang QL, Wang
JF, Zheng FF and Lu YG: Notch-4 contributes to the metastasis of
salivary adenoid cystic carcinoma. Oncol Rep. 24:363–368.
2010.PubMed/NCBI
|
|
26
|
Jakate AS, Einhaus CM, DeAnglis AP,
Retzinger GS and Desai PB: Preparation, characterization, and
preliminary application of fibrinogen-coated olive oil droplets for
the targeted delivery of docetaxel to solid malignancies. Cancer
Res. 63:7314–7320. 2003.PubMed/NCBI
|
|
27
|
Iqbal S, Lenz HJ, Gandara DR, Shibata SI,
Groshen S, Synold TW and Newman EM: A phase I trial of oxaliplatin
in combination with docetaxel in patients with advanced solid
tumors. Cancer Chemother Pharmacol. 72:85–91. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Salazar R, Morales S, Gil-Martín M,
Aguirre E, Oaknin A, Garcia M, Callies S, Wickremsinhe ER, Benhadji
KA and Llombart A: Phase 1 dose escalation and pharmacokinetic
evaluation of oral gemcitabine prodrug (LY2334737) in combination
with docetaxel in patients with advanced solid tumors. Cancer
Chemother Pharmacol. 73:1205–1215. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zu S, Ma W, Xiao P, Cui Y, Ma T, Zhou C
and Zhang H: Evaluation of docetaxel-sensitive and
docetaxel-resistant proteomes in PC-3 cells. Urol Int. 95:114–119.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mahon KL, Lin HM, Castillo L, Lee BY,
Lee-Ng M, Chatfield MD, Chiam K, Breit SN, Brown DA, Molloy MP, et
al: Cytokine profiling of docetaxel-resistant castration-resistant
prostate cancer. Br J Cancer. 112:1340–1348. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang Z, Li Y, Ahmad A, Banerjee S, Azmi
AS, Kong D, Wojewoda C, Miele L and Sarkar FH: Downregulation of
Notch-1 is associated with Akt and FoxM1 in inducing cell growth
inhibition and apoptosis in prostate cancer cells. J Cell Biochem.
112:78–88. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hour TC, Chung SD, Kang WY, Lin YC, Chuang
SJ, Huang AM, Wu WJ, Huang SP, Huang CY and Pu YS: EGFR mediates
docetaxel resistance in human castration-resistant prostate cancer
through the Akt-dependent expression of ABCB1 (MDR1). Arch Toxicol.
89:591–605. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sonego M, Gajendra S, Parsons M, Ma Y,
Hobbs C, Zentar MP, Williams G, Machesky LM, Doherty P and Lalli G:
Fascin regulates the migration of subventricular zone-derived
neuroblasts in the postnatal brain. J Neurosci. 33:12171–12185.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ghebeh H, Al-Khaldi S, Olabi S, Al-Dhfyan
A, Al-Mohanna F, Barnawi R, Tulbah A, Al-Tweigeri T, Ajarim D and
Al-Alwan M: Fascin is involved in the chemotherapeutic resistance
of breast cancer cells predominantly via the PI3K/Akt pathway. Br J
Cancer. 111:1552–1561. 2014. View Article : Google Scholar : PubMed/NCBI
|
